# Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

> **NCT04728698** · PHASE2 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Covid19
- ARDS

## Interventions

- **DRUG:** COVI-MSC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04728698
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Replaced by a different protocol.
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728698, "Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04728698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*